Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Saturday, 13'th Sep 2025
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
02:51pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such inve
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
12:43am, Wednesday, 10'th Sep 2025
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the head
Investors can contact the law firm at no cost to learn more about recovering their losses
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
02:21pm, Tuesday, 09'th Sep 2025
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Top 3 Health Care Stocks You'll Regret Missing In Q3
09:12am, Tuesday, 09'th Sep 2025
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Is Summit Therapeutics a Buy, Sell, or Hold Now?
05:51am, Tuesday, 09'th Sep 2025
A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.
Summit Therapeutics (SMMT) WCLC Update Call (Transcript)
03:36pm, Monday, 08'th Sep 2025
Summit Therapeutics (NASDAQ:SMMT ) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of
Summit Therapeutics shares fall as lung cancer trial results disappoint
12:36pm, Monday, 08'th Sep 2025
Summit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stoc
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:10am, Monday, 08'th Sep 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
06:08am, Sunday, 07'th Sep 2025
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrate
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
07:00am, Wednesday, 03'rd Sep 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clin
3 No-Brainer Stocks to Buy Right Now
06:45am, Sunday, 31'st Aug 2025
Some decisions require lengthy deliberations and extensive analysis. Others don't.
Summit Therapeutics price target raised to $50 from $44 at H.C. Wainwright
06:15am, Wednesday, 27'th Aug 2025
H.C. Wainwright raised the firm's price target on Summit Therapeutics to $50 from $44 and keeps a Buy rating on the shares. The firm believes Akeso's HARMONi-A study for ivonescimab validates the Chin
